Sacituzumab govitecan in HR+ and HER2-metastatic breast cancer: for all or for some?

[1] First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study [J]. ANNALS OF ONCOLOGY, 2005, 16 (06) : 899 - 908

[2] Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 7794 - 7803

[3] Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy [J]. BREAST CARE, 2011, 6 (04) : 279 - 283

[4] Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2014, 43 (03) : 937 - 948

[5] Kucukoztas N, 2016, J BUON, V21, P1076

[6] Informative Censoring of Progression-Free Survival Data in the TROPiCS-02 Trial: An Unrecognized Bias [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (08) : 1629 - +

[7] Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[8] Meirson Tomer, 2023, Lancet Oncol, V24, P589, DOI 10.1016/S1470-2045(23)00165-1

[9] Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) : 1 - 17

[10] Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02) a randomised, open-label, multicentre, phase 3 trial [J]. LANCET, 2023, 402 (10411) : 1423 - 1433

[1] First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study [J]. ANNALS OF ONCOLOGY, 2005, 16 (06) : 899 - 908

[2] Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 7794 - 7803

[3] Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy [J]. BREAST CARE, 2011, 6 (04) : 279 - 283

[4] Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2014, 43 (03) : 937 - 948

[5] Kucukoztas N, 2016, J BUON, V21, P1076

[6] Informative Censoring of Progression-Free Survival Data in the TROPiCS-02 Trial: An Unrecognized Bias [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (08) : 1629 - +

[7] Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[8] Meirson Tomer, 2023, Lancet Oncol, V24, P589, DOI 10.1016/S1470-2045(23)00165-1

[9] Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) : 1 - 17

[10] Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02) a randomised, open-label, multicentre, phase 3 trial [J]. LANCET, 2023, 402 (10411) : 1423 - 1433